alogliptin sold brand names nesina oral antidiabetic drug inhibitor gliptin alogliptin decrease risk heart attack stroke like members gliptin class causes little weight gain exhibits relatively little risk hypoglycemia relatively modest glucoselowering activity alogliptin gliptins commonly used combination metformin people whose diabetes adequately controlled metformin april us food drug administration fda added warning increased risk heart developed syrrx company acquired takeda pharmaceutical company commonly prescribed medication united states million alogliptin dipeptidyl inhibitor decreases blood sugar similar adverse events include mild hypoglycemia based clinical alogliptin associated increased weight increased risk cardiovascular may also cause joint pain severe april us food drug administration fda added warning increased risk heart december takeda submitted new drug application nda alogliptin united states food drug administration positive results phase iii clinical september company also filed approval winning approval april company also filed marketing authorization application maa elsewhere outside united states withdrawn june needing first usfda nda failed gain approval followed pair ndas one alogliptin second combination alogliptin pioglitazone july takeda received negative response usfda ndas citing need additional fda approved drug three formulations standalone brandname nesina combined metformin using name kazano combined pioglitazone osenicitation needed httpsenwikipediaorgwikialogliptin